Imagenebio Stock Performance
| IMA Stock | 7.11 0.26 3.80% |
The company retains a Market Volatility (i.e., Beta) of 0.46, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, ImageneBio's returns are expected to increase less than the market. However, during the bear market, the loss of holding ImageneBio is expected to be smaller as well. At this point, ImageneBio has a negative expected return of -0.12%. Please make sure to check out ImageneBio's potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if ImageneBio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ImageneBio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return (2.42) | Year To Date Return 1.33 | Ten Year Return (98.22) | All Time Return (98.22) |
Last Split Factor 1:12 | Last Split Date 2025-07-28 |
1 | Brokerages Set ImageneBio, Inc. Target Price at 26.50 | 11/25/2025 |
2 | Acquisition by Slattery Joseph P of 16000 shares of ImageneBio at 5.99 subject to Rule 16b-3 | 12/24/2025 |
3 | Acquisition by Erin Butler of 22500 shares of ImageneBio at 7.11 subject to Rule 16b-3 | 12/30/2025 |
4 | ImageneBio Insider Confidence Rewarded, Stock Hits US76m Market Cap | 12/31/2025 |
5 | Disposition of 23419 shares by Orbimed Advisors Llc of ImageneBio at 3.71 subject to Rule 16b-3 | 01/20/2026 |
6 | Macquarie says this mineral sands miner could deliver better than 80 percent returns | 02/04/2026 |
7 | World-Renowned Physicians and Scientific Leaders Convene in Texas this April for IMAs 5th Annual Medical Education Conference | 02/12/2026 |
| Begin Period Cash Flow | 121.2 M | |
| Total Cashflows From Investing Activities | -34.9 M |
ImageneBio | Build AI portfolio with ImageneBio Stock |
ImageneBio Relative Risk vs. Return Landscape
If you would invest 770.00 in ImageneBio on November 15, 2025 and sell it today you would lose (85.00) from holding ImageneBio or give up 11.04% of portfolio value over 90 days. ImageneBio is generating negative expected returns assuming volatility of 3.8252% on return distribution over 90 days investment horizon. In other words, 34% of stocks are less volatile than ImageneBio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
ImageneBio Target Price Odds to finish over Current Price
The tendency of ImageneBio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.11 | 90 days | 7.11 | about 38.75 |
Based on a normal probability distribution, the odds of ImageneBio to move above the current price in 90 days from now is about 38.75 (This ImageneBio probability density function shows the probability of ImageneBio Stock to fall within a particular range of prices over 90 days) .
ImageneBio Price Density |
| Price |
Predictive Modules for ImageneBio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ImageneBio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ImageneBio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ImageneBio is not an exception. The market had few large corrections towards the ImageneBio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ImageneBio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ImageneBio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.26 | |
β | Beta against Dow Jones | 0.46 | |
σ | Overall volatility | 0.63 | |
Ir | Information ratio | -0.08 |
ImageneBio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ImageneBio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ImageneBio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ImageneBio generated a negative expected return over the last 90 days | |
| ImageneBio has high historical volatility and very poor performance | |
| ImageneBio was previously known as Ikena Oncology and was traded on NASDAQ Exchange under the symbol IKNA. | |
| The company reported the last year's revenue of 3.5 M. Reported Net Loss for the year was (49.23 M) with profit before taxes, overhead, and interest of 4.3 M. | |
| ImageneBio generates negative cash flow from operations | |
| ImageneBio has a frail financial position based on the latest SEC disclosures | |
| About 14.0% of the company shares are held by company insiders | |
| Latest headline from prnewswire.com: World-Renowned Physicians and Scientific Leaders Convene in Texas this April for IMAs 5th Annual Medical Education Conference |
ImageneBio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ImageneBio Stock often depends not only on the future outlook of the current and potential ImageneBio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ImageneBio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 48.3 M | |
| Cash And Short Term Investments | 124.4 M |
ImageneBio Fundamentals Growth
ImageneBio Stock prices reflect investors' perceptions of the future prospects and financial health of ImageneBio, and ImageneBio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImageneBio Stock performance.
| Operating Margin | (5.01) % | ||||
| Current Valuation | 111.51 M | ||||
| Shares Outstanding | 11.18 M | ||||
| Price To Sales | 21.32 X | ||||
| Revenue | 3.5 M | ||||
| Gross Profit | 4.3 M | ||||
| EBITDA | (35.47 M) | ||||
| Net Income | (49.23 M) | ||||
| Total Debt | 7.52 M | ||||
| Book Value Per Share | (0.43) X | ||||
| Cash Flow From Operations | (46 M) | ||||
| Earnings Per Share | (4.33) X | ||||
| Market Capitalization | 91.69 M | ||||
| Total Asset | 141.51 M | ||||
| Retained Earnings | (331.62 M) | ||||
| Working Capital | (4.74 M) | ||||
About ImageneBio Performance
By analyzing ImageneBio's fundamental ratios, stakeholders can gain valuable insights into ImageneBio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ImageneBio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ImageneBio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.25) | (0.27) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.33) | (0.32) |
Things to note about ImageneBio performance evaluation
Checking the ongoing alerts about ImageneBio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ImageneBio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImageneBio generated a negative expected return over the last 90 days | |
| ImageneBio has high historical volatility and very poor performance | |
| ImageneBio was previously known as Ikena Oncology and was traded on NASDAQ Exchange under the symbol IKNA. | |
| The company reported the last year's revenue of 3.5 M. Reported Net Loss for the year was (49.23 M) with profit before taxes, overhead, and interest of 4.3 M. | |
| ImageneBio generates negative cash flow from operations | |
| ImageneBio has a frail financial position based on the latest SEC disclosures | |
| About 14.0% of the company shares are held by company insiders | |
| Latest headline from prnewswire.com: World-Renowned Physicians and Scientific Leaders Convene in Texas this April for IMAs 5th Annual Medical Education Conference |
- Analyzing ImageneBio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImageneBio's stock is overvalued or undervalued compared to its peers.
- Examining ImageneBio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImageneBio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImageneBio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImageneBio's stock. These opinions can provide insight into ImageneBio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ImageneBio Stock analysis
When running ImageneBio's price analysis, check to measure ImageneBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImageneBio is operating at the current time. Most of ImageneBio's value examination focuses on studying past and present price action to predict the probability of ImageneBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImageneBio's price. Additionally, you may evaluate how the addition of ImageneBio to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |